ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2021-4-112-122ssmu-4588Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESПриверженность модификации образа жизни при неалкогольной жировой болезни печениAdherence to lifestyle modification in patients with nonalcoholic fatty liver diseasehttps://orcid.org/0000-0001-9976-573XАндреевК. А.AndreevK. A.

инспектор, управление по развитию регионального здравоохранения и медицинской деятельности, 

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

kivi2104@gmail.comhttps://orcid.org/0000-0002-6225-2444СкирденкоЮ. П.SkirdenkoYu. P.

канд. мед. наук, ассистент кафедры факультетской терапии и гастроэнтерологии,

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

https://orcid.org/0000-0002-3758-4930НиколаевН. А.NikolaevN. A.

д-р мед. наук, доцент, профессор кафедры факультетской терапии и гастроэнтерологии, проректор по медицинской деятельности и региональному здравоохранению, 

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

https://orcid.org/0000-0002-6581-7017ЛивзанМ. А.LivzanM. A.

д-р мед. наук, профессор, зав. кафедрой факультетской терапии и гастроэнтерологии, ректор,

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

https://orcid.org/0000-0001-9703-9371ГорбенкоА. В.GorbenkoA. V.

инспектор, управление по развитию регионального здравоохранения и медицинской деятельности, 

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

https://orcid.org/0000-0002-0238-4664ФедоринМ. М.FedorinM. M.

инспектор, управление по развитию регионального здравоохранения и медицинской деятельности, 

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

https://orcid.org/0000-0002-7452-7230КролевецТ. С.KrolevetsT. S.

канд. мед. наук, ассистент кафедры факультетской терапии и гастроэнтерологии, 

644099, г. Омск, ул. Ленина, 12

12, Lenina Str., Omsk, 644099

Омский государственный медицинский университет (ОмГМУ)РоссияOmsk State Medical UniversityRussian Federation202103012022204112122Copyright © Андреев К.А., Скирденко Ю.П., Николаев Н.А., Ливзан М.А., Горбенко А.В., Федорин М.М., Кролевец Т.С., 20222022Андреев К.А., Скирденко Ю.П., Николаев Н.А., Ливзан М.А., Горбенко А.В., Федорин М.М., Кролевец Т.С.Andreev K.A., Skirdenko Y.P., Nikolaev N.A., Livzan M.A., Gorbenko A.V., Fedorin M.M., Krolevets T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/4588

Неалкогольная жировая болезнь печени (НАЖБП) вносит серьезный вклад в заболеваемость и смертность трудоспособного населения развитых стран. При отсутствии эффективных фармакологических подходов ведущую роль в лечении НАЖБП играет модификация образа жизни, в первую очередь последовательная и постепенная потеря массы тела, а также ее поддержание. Качественный и количественный состав диеты, уровень физической активности, а главное, регулярность выполнения мероприятий по модификации образа жизни являются залогом успешного ведения пациентов с НАЖБП.

На сегодняшний день исследований, посвященных изучению вопросов приверженности мероприятиям по изменению образа жизни у данной группы больных, крайне мало, что во многом связано со скудностью методологического инструментария. Рекомендованный российским научным медицинским обществом терапевтов опросник количественной оценки приверженности лечению «КОП-25» позволяет оценить как приверженность терапии в целом, так и по отдельным ключевым компонентам (приверженность лекарственной терапии, приверженность медицинскому сопровождению и приверженность модификации образа жизни), что требует изучения, учитывая особенности терапевтических стратегий при НАЖБП. 

Nonalcoholic fatty liver disease (NAFLD) makes a major impact on morbidity and mortality among the workingage population in developed countries. In the lack of effective pharmacological methods, the leading role in treatment of NAFLD belongs to lifestyle modification, consistent and gradual weight loss, and its maintenance. The qualitative and quantitative structure of the diet, intensity of physical activity, and most importantly, regularity and consistency of implementation of lifestyle modification activities are the key to successful management of patients with NAFLD.

To date, there are very few studies on adherence to lifestyle modification activities in this group of patients, which is mainly due to a deficiency of methodological tools. The questionnaire “QAA-25” recommended by the Russian Scientific Medical Society of Therapists for quantitative assessment of adherence to treatment allows to assess both adherence to therapy in general and adherence to its individual components (adherence to drug therapy, adherence to medical counseling, and adherence to lifestyle modification), which requires further study taking into account features of therapeutic strategies in treating NAFLD. 

неалкогольная жировая болезнь печениприверженностьмодификация образа жизниинсулинорезистентностьметаболический синдромnonalcoholic fatty liver diseaselifestyle modificationadherenceinsulin resistancemetabolic syndromeПубликация подготовлена за счет финансирования по гранту Президента России для государственной поддержки ведущих научных школ НШ-2558.2020.7 (соглашение № 075-15- 2020-036 от 17.03.2020) «Разработка технологии здоровьесбережения коморбидного больного гастроэнтерологического профиля на основе контроля приверженности»The study was supported by the grant of the President of the Russian Federation for the state support for the leading scientific schools of the Russian Federation SS-2558.2020.7 (Agreement No. 075-15-2020- 036 of 17.03.2020) “Development of Health-Preserving Technology for a Comorbid Gastroenterological Patient Based on Adherence Control”.ReferencesByrne C.D., Targher G. NAFLD: A multisystem disease. Journal of Hepatology. 2015; 61 (Suppl. 1): 47–64. DOI: 10.1016/j.jhep.2014.12.012.Byrne C.D., Targher G. NAFLD: A multisystem disease. Journal of Hepatology. 2015; 61 (Suppl. 1): 47–64. DOI: 10.1016/j.jhep.2014.12.012.Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальня и клиническая гастроэнтерология. 2014; 108 (8): 27–33.Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Экспериментальня и клиническая гастроэнтерология. 2014; 108 (8): 27–33.Rodriguez B., Torres D.M., Harrison S.A. Physical activity: An essential component of lifestyle modification in NAFLD. Nature Reviews Gastroenterology and Hepatology. 2012; 9 (12): 726–731. DOI: 10.1038/nrgastro.2012.200.Rodriguez B., Torres D.M., Harrison S.A. Physical activity: An essential component of lifestyle modification in NAFLD. Nature Reviews Gastroenterology and Hepatology. 2012; 9 (12): 726–731. DOI: 10.1038/nrgastro.2012.200.Bedogni G., Nobili V., Tiribelli C. Epidemiology of fatty liver: An update. World Journal of Gastroenterology. 2014; 20 (27): 9050–9054. DOI: 10.3748/wjg.v20.i27.9050.Bedogni G., Nobili V., Tiribelli C. Epidemiology of fatty liver: An update. World Journal of Gastroenterology. 2014; 20 (27): 9050–9054. DOI: 10.3748/wjg.v20.i27.9050.Pappachan J.M., Babu S., Krishnan B., Ravindran N.C. Non-alcoholic fatty liver disease: a clinical update. J. Clin. Transl. Hepatol. 2017; 5 (4): 384–393. DOI: 10.14218/jcth.2017.00013.Pappachan J.M., Babu S., Krishnan B., Ravindran N.C. Non-alcoholic fatty liver disease: a clinical update. J. Clin. Transl. Hepatol. 2017; 5 (4): 384–393. DOI: 10.14218/jcth.2017.00013.Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2012; 57 (1): 157–166. DOI: 10.1016/j.jhep.2012.02.023.Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2012; 57 (1): 157–166. DOI: 10.1016/j.jhep.2012.02.023.Labrecque D.R., Abbas Z., Anania F., Ferenci P., Khan A.G., Goh K.L., Hamid S.S., Isakov V., Lizarzabal M., Peñaranda M.M., Ramos J.F.R., Sarin S., Stimac D., Thomson A.B.R., Umar M., Krabshuis J., Lemair A. World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2014; 48 (6): 467–473. DOI: 10.1097/MCG.0000000000000116.Labrecque D.R., Abbas Z., Anania F., Ferenci P., Khan A.G., Goh K.L., Hamid S.S., Isakov V., Lizarzabal M., Peñaranda M.M., Ramos J.F.R., Sarin S., Stimac D., Thomson A.B.R., Umar M., Krabshuis J., Lemair A. World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2014; 48 (6): 467–473. DOI: 10.1097/MCG.0000000000000116.Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., Anvari M., Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2019; 17 (6): 1040–1060. DOI: 10.1016/j.cgh.2018.10.017.Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., Anvari M., Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2019; 17 (6): 1040–1060. DOI: 10.1016/j.cgh.2018.10.017.Li Y., Liu L., Wang B., Wang J., Chen D. Metformin in nonalcoholic fatty liver disease: A systematic review and metaanalysis. Biomed. Reports. 2013; 1 (1): 57–64. DOI: 10.3892/br.2012.18.Li Y., Liu L., Wang B., Wang J., Chen D. Metformin in nonalcoholic fatty liver disease: A systematic review and metaanalysis. Biomed. Reports. 2013; 1 (1): 57–64. DOI: 10.3892/br.2012.18.Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K., Abouda G., Aldersley M.A., Stocken D., Gough S.C., Tomlinson J.W., Brown R.M., Hübscher S.G., Newsome P.N. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387 (10019): 679–690. DOI: 10.1016/S0140-6736(15)00803-X.Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K., Abouda G., Aldersley M.A., Stocken D., Gough S.C., Tomlinson J.W., Brown R.M., Hübscher S.G., Newsome P.N. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387 (10019): 679–690. DOI: 10.1016/S0140-6736(15)00803-X.Rakoski M.O., Singal A.G., Rogers M.A.M., Conjeevaram H. Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol. Ther. 2010; 32 (10): 1211–1221. DOI: 10.1111/j.1365-2036.2010.04467.x.Rakoski M.O., Singal A.G., Rogers M.A.M., Conjeevaram H. Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol. Ther. 2010; 32 (10): 1211–1221. DOI: 10.1111/j.1365-2036.2010.04467.x.Boettcher E., Csako G., Pucino F., Wesley R., Loomba R. Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol. Ther. 2012; 35 (1): 66–75. DOI: 10.1111/j.1365-2036.2011.04912.x.Boettcher E., Csako G., Pucino F., Wesley R., Loomba R. Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol. Ther. 2012; 35 (1): 66–75. DOI: 10.1111/j.1365-2036.2011.04912.x.Mazidi M., Kengne A.P. Higher adherence to plant-based diets are associated with lower likelihood of fatty liver. Clin. Nutr. 2019; 38 (4): 1672–1677. DOI: 10.1016/j.clnu.2018.08.010.Mazidi M., Kengne A.P. Higher adherence to plant-based diets are associated with lower likelihood of fatty liver. Clin. Nutr. 2019; 38 (4): 1672–1677. DOI: 10.1016/j.clnu.2018.08.010.Khalatbari-Soltani S.. Imamura F., Brage S., De Lucia Rolfe E., Griffin S.J., Wareham N.J., Marques-Vidal P., Forouhi N.G. The association between adherence to the Mediterranean diet and hepatic steatosis: Cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Med. 2019; 17 (1): 19. DOI: 10.1186/s12916-019-1251-7.Khalatbari-Soltani S.. Imamura F., Brage S., De Lucia Rolfe E., Griffin S.J., Wareham N.J., Marques-Vidal P., Forouhi N.G. The association between adherence to the Mediterranean diet and hepatic steatosis: Cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Med. 2019; 17 (1): 19. DOI: 10.1186/s12916-019-1251-7.Драпкина О.М., Ливзан М.А., Мартынов А.И., Моисеев С.В., Николаев Н.А., Скирденко Ю.П. от имени Рабочей группы и Комитета экспертов-соавторов: Бунова С.С., Викторова И.А., Драпкина О.М., Задионченко В.С., Лазебник Л.Б., Ливзан М.А., Малявин А.Г., Мартынов А.И., Моисеев С.В., Нелидова А.В., Нечаева Г.И., Николаев Н.А., Пушкарёва Л.А., Ребров А.П., Сайфутдинов Р.И., Скир денко Ю.П., Совалкин В.И., Терентьев В.П., Тюрин В.П., Уразов В.П., Федосеев Г.Б., Ягода А.В., Якушин С.С., Ясницкий Л.Н. Первый Российский консенсус по количественной оценке приверженности к лечению: основные положения, алгоритмы и рекомендации. Медицинский вестник Северного Кавказа. 2018; 13 (1.2): 259–271. DOI: 10.14300/mnnc.2018.13039.Драпкина О.М., Ливзан М.А., Мартынов А.И., Моисеев С.В., Николаев Н.А., Скирденко Ю.П. от имени Рабочей группы и Комитета экспертов-соавторов: Бунова С.С., Викторова И.А., Драпкина О.М., Задионченко В.С., Лазебник Л.Б., Ливзан М.А., Малявин А.Г., Мартынов А.И., Моисеев С.В., Нелидова А.В., Нечаева Г.И., Николаев Н.А., Пушкарёва Л.А., Ребров А.П., Сайфутдинов Р.И., Скир денко Ю.П., Совалкин В.И., Терентьев В.П., Тюрин В.П., Уразов В.П., Федосеев Г.Б., Ягода А.В., Якушин С.С., Ясницкий Л.Н. Первый Российский консенсус по количественной оценке приверженности к лечению: основные положения, алгоритмы и рекомендации. Медицинский вестник Северного Кавказа. 2018; 13 (1.2): 259–271. DOI: 10.14300/mnnc.2018.13039.Marchesini G., Day C.P., Dufour J.F., Canbay A., Nobili V., Ratziu V., Tilg H., Roden M., Gastaldelli A., Yki-Jarvinen H., Schick F., Vettor R., Fruhbeck G., Mathus-Vliegen L. EASL-EASD-easo clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64 (6): 1388–1402. DOI: 10.1016/j.jhep.2015.11.004.Marchesini G., Day C.P., Dufour J.F., Canbay A., Nobili V., Ratziu V., Tilg H., Roden M., Gastaldelli A., Yki-Jarvinen H., Schick F., Vettor R., Fruhbeck G., Mathus-Vliegen L. EASL-EASD-easo clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64 (6): 1388–1402. DOI: 10.1016/j.jhep.2015.11.004.Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clinical Nutrition. 2014; 33 (2): 186–190. DOI: 10.1016/j.clnu.2013.11.003.Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: The good and the bad. Clinical Nutrition. 2014; 33 (2): 186–190. DOI: 10.1016/j.clnu.2013.11.003.Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Влияние на параметры абдоминального ожирения у больных метаболическим синдромом: фокус на приверженность диетическим рекомендациям. Лечащий врач. 2010; 7: 29–34.Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Влияние на параметры абдоминального ожирения у больных метаболическим синдромом: фокус на приверженность диетическим рекомендациям. Лечащий врач. 2010; 7: 29–34.Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99 (5): 1408–1413. DOI: 10.1016/0016-5085(90)91169-7.Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99 (5): 1408–1413. DOI: 10.1016/0016-5085(90)91169-7.Zelber-Sagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., Leshno M., Blendis L., Halpern Z., Oren R. A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2006; 4 (5): 639–644. DOI: 10.1016/j.cgh.2006.02.004.Zelber-Sagi S., Kessler A., Brazowsky E., Webb M., Lurie Y., Santo M., Leshno M., Blendis L., Halpern Z., Oren R. A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2006; 4 (5): 639–644. DOI: 10.1016/j.cgh.2006.02.004.Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. Journal of Hepatology. 2012; 56 (1): 255– 266. DOI: 10.1016/j.jhep.2011.06.010.Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. Journal of Hepatology. 2012; 56 (1): 255– 266. DOI: 10.1016/j.jhep.2011.06.010.Rodriguez-Ramiro I., Vauzour D., Minihane A.M. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. Proceedings of the Nutrition Society. 2016; 75 (1): 47–60. DOI: 10.1017/S0029665115004218.Rodriguez-Ramiro I., Vauzour D., Minihane A.M. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. Proceedings of the Nutrition Society. 2016; 75 (1): 47–60. DOI: 10.1017/S0029665115004218.Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., Fagà E., Silli B., Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37 (4): 909–916. DOI: 10.1053/jhep.2003.50132.Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., Fagà E., Silli B., Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37 (4): 909–916. DOI: 10.1053/jhep.2003.50132.Kang H., Greenson J.K., Omo J.T., Chao C., Peterman D., Anderson L., Foess-Wood L., Sherbondy M.A., Conjeevaram H.S. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am. J. Gastroenterol. 2006; 101 (10): 2247–2253. DOI: 10.1111/j.1572-0241.2006.00719.x.Kang H., Greenson J.K., Omo J.T., Chao C., Peterman D., Anderson L., Foess-Wood L., Sherbondy M.A., Conjeevaram H.S. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am. J. Gastroenterol. 2006; 101 (10): 2247–2253. DOI: 10.1111/j.1572-0241.2006.00719.x.Krolevets T.S., Livzan M.A., Kolbina M.V. Matrix metalloproteinases and their tissue inhibitors in patients with nonalcoholic fatty liver disease. J. Pharm. Pharmacol. 2016; 4 (12). DOI: 10.17265/2328-2150/2016.12.008.Krolevets T.S., Livzan M.A., Kolbina M.V. Matrix metalloproteinases and their tissue inhibitors in patients with nonalcoholic fatty liver disease. J. Pharm. Pharmacol. 2016; 4 (12). DOI: 10.17265/2328-2150/2016.12.008.Ефременко Е.С., Титов Д.С., Nikonov D.A., Сидоров Г.Г., Андреев К.А. Глутатион-зависимые механизмы антиоксидантной защиты при алкоголизме. Международный журнал прикладных и фундаментальных исследований. 2019; 4: 105–108.Ефременко Е.С., Титов Д.С., Nikonov D.A., Сидоров Г.Г., Андреев К.А. Глутатион-зависимые механизмы антиоксидантной защиты при алкоголизме. Международный журнал прикладных и фундаментальных исследований. 2019; 4: 105–108.Eilat-Adar S., Sinai T., Yosefy C., Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients. 2013; 5 (9): 3646–3683. DOI: 10.3390/nu5093646.Eilat-Adar S., Sinai T., Yosefy C., Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients. 2013; 5 (9): 3646–3683. DOI: 10.3390/nu5093646.Ливзан М.А., Николаев Н.А., Скирденко Ю.П., Федорин М.М., Горбенко А.В., Андреев К.А., Андреева Е.К., Иванов А.И., Ивахненко А.Т. Пищевое поведение в студенческой среде. Кремлевская медицина. Клинический вестник. 2019; 2: 13–16. DOI: 10.26269/tvs8-by34.Ливзан М.А., Николаев Н.А., Скирденко Ю.П., Федорин М.М., Горбенко А.В., Андреев К.А., Андреева Е.К., Иванов А.И., Ивахненко А.Т. Пищевое поведение в студенческой среде. Кремлевская медицина. Клинический вестник. 2019; 2: 13–16. DOI: 10.26269/tvs8-by34.Koch M., Borggrefe J., Barbaresko J., Groth G., Jacobs G., Siegert S., Lieb W., Müller M.J., Bosy-Westphal A., Heller M., N̈othlings U. Dietary patterns associated with magnetic resonance imaging-determined liver fat content in a general population study 1–3. Am. J. Clin. Nutr. 2014; 99 (2): 369–377. DOI: 10.3945/ajcn.113.070219.Koch M., Borggrefe J., Barbaresko J., Groth G., Jacobs G., Siegert S., Lieb W., Müller M.J., Bosy-Westphal A., Heller M., N̈othlings U. Dietary patterns associated with magnetic resonance imaging-determined liver fat content in a general population study 1–3. Am. J. Clin. Nutr. 2014; 99 (2): 369–377. DOI: 10.3945/ajcn.113.070219.Yang C.Q., Shu L., Wang S., Wang J.J., Zhou Y., Xuan Y.J., Wang S.F. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in Chinese adults. Nutrients. 2015; 7 (6): 4778–4791. DOI: 10.3390/nu7064778.Yang C.Q., Shu L., Wang S., Wang J.J., Zhou Y., Xuan Y.J., Wang S.F. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in Chinese adults. Nutrients. 2015; 7 (6): 4778–4791. DOI: 10.3390/nu7064778.Cicero A.F.G., Colletti A., Bajraktari G., Descamps O., Djuric D.M., Ezhov M., Fras Z., Katsiki N., Langlois M., Latkovskis G., Panagiotakos D.B., Paragh G., Mikhailidis D.P., Mitchenko O., Paulweber B., Pella D., Pitsavos C., Reiner Ž., Ray K.K., Rizzo M., Sahebkar A., Serban M.C., Sperling L.S., Toth P.P., Vinereanu D., Vrablík M., Wong N.D., Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr. Rev. 2017; 75 (9): 731–767. DOI: 10.1093/nutrit/nux047.Cicero A.F.G., Colletti A., Bajraktari G., Descamps O., Djuric D.M., Ezhov M., Fras Z., Katsiki N., Langlois M., Latkovskis G., Panagiotakos D.B., Paragh G., Mikhailidis D.P., Mitchenko O., Paulweber B., Pella D., Pitsavos C., Reiner Ž., Ray K.K., Rizzo M., Sahebkar A., Serban M.C., Sperling L.S., Toth P.P., Vinereanu D., Vrablík M., Wong N.D., Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr. Rev. 2017; 75 (9): 731–767. DOI: 10.1093/nutrit/nux047.Martínez-González M.A., Sánchez-Tainta A., Corella D., Salas-Salvadó J., Ros E., Arós F., Gómez-Gracia E., Fiol M., Lamuela-Raventós R.M., Schröder H., Lapetra J., Serra-Majem L., Pinto X., Ruiz-Gutierrez V., Estruch R. A provegetarian food pattern and reduction in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. American Journal of Clinical Nutrition. 2014; 100 (Suppl. 1): 320–328. DOI: 10.3945/ajcn.113.071431.Martínez-González M.A., Sánchez-Tainta A., Corella D., Salas-Salvadó J., Ros E., Arós F., Gómez-Gracia E., Fiol M., Lamuela-Raventós R.M., Schröder H., Lapetra J., Serra-Majem L., Pinto X., Ruiz-Gutierrez V., Estruch R. A provegetarian food pattern and reduction in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. American Journal of Clinical Nutrition. 2014; 100 (Suppl. 1): 320–328. DOI: 10.3945/ajcn.113.071431.Fraser G.E. Vegetarian diets: What do we know of their effects on common chronic diseases? American Journal of Clinical Nutrition. 2009; 89 (5): 1607–1612. DOI: 10.3945/ajcn.2009.26736K.Fraser G.E. Vegetarian diets: What do we know of their effects on common chronic diseases? American Journal of Clinical Nutrition. 2009; 89 (5): 1607–1612. DOI: 10.3945/ajcn.2009.26736K.Chiu T.H., Lin M.N., Pan W.H., Chen Y.C., Lin C.L. Vegetarian diet, food substitution, and nonalcoholic fatty liver. Tzu. Chi Med. J. 2018; 30 (2): 102–109. DOI: 10.4103/tcmj.tcmj_109_17.Chiu T.H., Lin M.N., Pan W.H., Chen Y.C., Lin C.L. Vegetarian diet, food substitution, and nonalcoholic fatty liver. Tzu. Chi Med. J. 2018; 30 (2): 102–109. DOI: 10.4103/tcmj.tcmj_109_17.Choi S.H., Oh D.J., Kwon K.H., Lee J.K., Koh M.S., Lee J.H., Kang H.W. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): A cross-sectional study between Buddhist priests and the general population. Turkish J. Gastroenterol. 2015; 26 (4): 336–343. DOI: 10.5152/tjg.2015.0046.Choi S.H., Oh D.J., Kwon K.H., Lee J.K., Koh M.S., Lee J.H., Kang H.W. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): A cross-sectional study between Buddhist priests and the general population. Turkish J. Gastroenterol. 2015; 26 (4): 336–343. DOI: 10.5152/tjg.2015.0046.Alferink L.J.M., Kiefte-De Jong J.C., Erler N.S., Veldt B.J., Schoufour J.D., De Knegt R.J., Ikram M.A., Metselaar H.J., Janssen H.L.A., Franco O.H., Darwish M.S. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: The Rotterdam Study. Gut. 2019; 68 (6): 1088–1098. DOI: 10.1136/gutjnl-2017-315940.Alferink L.J.M., Kiefte-De Jong J.C., Erler N.S., Veldt B.J., Schoufour J.D., De Knegt R.J., Ikram M.A., Metselaar H.J., Janssen H.L.A., Franco O.H., Darwish M.S. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: The Rotterdam Study. Gut. 2019; 68 (6): 1088–1098. DOI: 10.1136/gutjnl-2017-315940.Anania C., Massimo Perla F., Olivero F., Pacifico L., Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2018; 24 (19): 2083–2094. DOI: 10.3748/wjg.v24.i19.2083.Anania C., Massimo Perla F., Olivero F., Pacifico L., Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2018; 24 (19): 2083–2094. DOI: 10.3748/wjg.v24.i19.2083.Serra-Majem L., Ortiz-Andrellucchi A., Sánchez-Villegas A. Mediterranean diet. Encyclopedia of Food Security and Sustainability. 2018. DOI: 10.1016/B978-0-08-100596-5.22054-4.Serra-Majem L., Ortiz-Andrellucchi A., Sánchez-Villegas A. Mediterranean diet. Encyclopedia of Food Security and Sustainability. 2018. DOI: 10.1016/B978-0-08-100596-5.22054-4.Papamiltiadous E.S., Roberts S.K., Nicoll A.J., Ryan M.C., Itsiopoulos C., Salim A., Tierney A.C. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): Study protocol. BMC Gastroenterol. 2016; 16: 14. DOI: 10.1186/s12876-016-0426-3.Papamiltiadous E.S., Roberts S.K., Nicoll A.J., Ryan M.C., Itsiopoulos C., Salim A., Tierney A.C. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): Study protocol. BMC Gastroenterol. 2016; 16: 14. DOI: 10.1186/s12876-016-0426-3.Teixeira J.S., Campos A.B.F., Cordeiro A., Pereira S.E., Saboya C.J., Ramalho A. Vitamin D nutritional status and its relationship with metabolic changes in adolescents and adults with severe obesity. Nutr. Hosp. 2018; 35 (4): 847–853. DOI: 10.20960/nh.1657.Teixeira J.S., Campos A.B.F., Cordeiro A., Pereira S.E., Saboya C.J., Ramalho A. Vitamin D nutritional status and its relationship with metabolic changes in adolescents and adults with severe obesity. Nutr. Hosp. 2018; 35 (4): 847–853. DOI: 10.20960/nh.1657.Cordeiro A., Pereira S., Saboya C.J., Ramalho A. Relationship between nonalcoholic fatty liver disease and vitamin D nutritional status in extreme obesity. Can. J. Gastroenterol. Hepatol. 2017; 2017: 9456897. DOI: 10.1155/2017/9456897.Cordeiro A., Pereira S., Saboya C.J., Ramalho A. Relationship between nonalcoholic fatty liver disease and vitamin D nutritional status in extreme obesity. Can. J. Gastroenterol. Hepatol. 2017; 2017: 9456897. DOI: 10.1155/2017/9456897.Villaça Chaves G., Pereira S.E., Saboya C.J., Ramalho A. Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity. Obes. Surg. 2008; 18 (4): 78–85. DOI: 10.1007/s11695-007-9361-2.Villaça Chaves G., Pereira S.E., Saboya C.J., Ramalho A. Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity. Obes. Surg. 2008; 18 (4): 78–85. DOI: 10.1007/s11695-007-9361-2.Moscatiello S., Di Luzio R., Bugianesi E., Suppini A., Hickman I.J., Di Domizio S., Dalle Grave R., Marchesini G. Cognitive-behavioral treatment of nonalcoholic fatty liver disease: A propensity score-adjusted observational study. Obesity. 2011; 19 (4): 763–770. DOI: 10.1038/oby.2010.254.Moscatiello S., Di Luzio R., Bugianesi E., Suppini A., Hickman I.J., Di Domizio S., Dalle Grave R., Marchesini G. Cognitive-behavioral treatment of nonalcoholic fatty liver disease: A propensity score-adjusted observational study. Obesity. 2011; 19 (4): 763–770. DOI: 10.1038/oby.2010.254.Greaves C.J., Sheppard K.E., Abraham C., Hardeman W., Roden M., Evans P.H., Schwarz P. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011; 11: 119. DOI: 10.1186/1471-2458-11-119.Greaves C.J., Sheppard K.E., Abraham C., Hardeman W., Roden M., Evans P.H., Schwarz P. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011; 11: 119. DOI: 10.1186/1471-2458-11-119.Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2011; 106 (3): 460–468. DOI: 10.1038/ajg.2010.488.Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2011; 106 (3): 460–468. DOI: 10.1038/ajg.2010.488.Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Zvibel I., Goldiner I., Blendis L., Halpern Z., Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. Hepatology. 2008; 48 (6): 1791–1798. DOI: 10.1002/hep.22525.Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Zvibel I., Goldiner I., Blendis L., Halpern Z., Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. Hepatology. 2008; 48 (6): 1791–1798. DOI: 10.1002/hep.22525.Anderson E.L., Howe L.D., Jones H.E., Higgins J.P.T., Lawlor D.A., Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One. 2015; 10 (10): e0140908. DOI: 10.1371/journal.pone.0140908.Anderson E.L., Howe L.D., Jones H.E., Higgins J.P.T., Lawlor D.A., Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One. 2015; 10 (10): e0140908. DOI: 10.1371/journal.pone.0140908.Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., Abrams S.H., Scheimann A.O., Sanyal A.J., Chalasani N., Tonascia J., Ünalp A., Clark J.M., Brunt E.M., Kleiner D.E., Hoofnagle J.H., Robuck P.R. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents the tonic randomized controlled trial. JAMA. 2011; 305 (16): 1659–1668. DOI: 10.1001/jama.2011.520.Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., Abrams S.H., Scheimann A.O., Sanyal A.J., Chalasani N., Tonascia J., Ünalp A., Clark J.M., Brunt E.M., Kleiner D.E., Hoofnagle J.H., Robuck P.R. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents the tonic randomized controlled trial. JAMA. 2011; 305 (16): 1659–1668. DOI: 10.1001/jama.2011.520.Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., Vos M.B. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019; 69 (6): 2672–2682. DOI: 10.1002/hep.30251.Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., Vos M.B. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019; 69 (6): 2672–2682. DOI: 10.1002/hep.30251.Hattar L.N., Wilson T.A., Tabotabo L.A., Smith E.O.B., Abrams S.H. Physical activity and nutrition attitudes in obese hispanic children with non-alcoholic steatohepatitis. World J. Gastroenterol. 2011; 17 (39): 4396–4403. DOI: 10.3748/wjg.v17.i39.4396.Hattar L.N., Wilson T.A., Tabotabo L.A., Smith E.O.B., Abrams S.H. Physical activity and nutrition attitudes in obese hispanic children with non-alcoholic steatohepatitis. World J. Gastroenterol. 2011; 17 (39): 4396–4403. DOI: 10.3748/wjg.v17.i39.4396.Kwak M.S., Kim D., Chung G.E., Kim W., Kim Y.J., Yoon J.H. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int. 2015; 35 (3): 944–952. DOI: 10.1111/liv.12552.Kwak M.S., Kim D., Chung G.E., Kim W., Kim Y.J., Yoon J.H. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int. 2015; 35 (3): 944–952. DOI: 10.1111/liv.12552.Golabi P., Otgonsuren M., Cable R., Felix S., Koenig A., Sayiner M., Younossi Z.M. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016; 14: 18. DOI: 10.1186/s12955-016-0420-z.Golabi P., Otgonsuren M., Cable R., Felix S., Koenig A., Sayiner M., Younossi Z.M. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016; 14: 18. DOI: 10.1186/s12955-016-0420-z.Гаус О.В., Ахмедов В.А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал. 2015; 1 (124): 132–137.Гаус О.В., Ахмедов В.А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал. 2015; 1 (124): 132–137.Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55 (6): 2005–2023. DOI: 10.1002/hep.25762.Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55 (6): 2005–2023. DOI: 10.1002/hep.25762.Katsagoni C.N., Georgoulis M., Papatheodoridis G.V., Panagiotakos D.B., Kontogianni M.D. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017; 68: 119–132. DOI: 10.1016/j.metabol.2016.12.006.Katsagoni C.N., Georgoulis M., Papatheodoridis G.V., Panagiotakos D.B., Kontogianni M.D. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017; 68: 119–132. DOI: 10.1016/j.metabol.2016.12.006.Medrano M., Cadenas-Sanchez C., Álvarez-Bueno C., Cavero-Redondo I., Ruiz J.R., Ortega F.B., Labayen I. Evidence-Based Exercise Recommendations to Reduce Hepatic Fat Content in Youth- a Systematic Review and Meta-Analysis. Progress in Cardiovascular Diseases. 2018; 61 (2): 222– 231. DOI: 10.1016/j.pcad.2018.01.013.Medrano M., Cadenas-Sanchez C., Álvarez-Bueno C., Cavero-Redondo I., Ruiz J.R., Ortega F.B., Labayen I. Evidence-Based Exercise Recommendations to Reduce Hepatic Fat Content in Youth- a Systematic Review and Meta-Analysis. Progress in Cardiovascular Diseases. 2018; 61 (2): 222– 231. DOI: 10.1016/j.pcad.2018.01.013.Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., Takano Y., Ueno T., Koga H., George J., Shiba N., Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J. Hepatol. 2017; 66 (1): 142–152. DOI: 10.1016/j.jhep.2016.08.023.Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., Takano Y., Ueno T., Koga H., George J., Shiba N., Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J. Hepatol. 2017; 66 (1): 142–152. DOI: 10.1016/j.jhep.2016.08.023.Golabi P., Locklear C.T., Austin P., Afdhal S., Byrns M., Gerber L., Younossi Z.M. Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology. 2016; 22 (27): 6318–6327. DOI: 10.3748/wjg.v22.i27.6318.Golabi P., Locklear C.T., Austin P., Afdhal S., Byrns M., Gerber L., Younossi Z.M. Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology. 2016; 22 (27): 6318–6327. DOI: 10.3748/wjg.v22.i27.6318.Kantartzis K., Thamer C., Peter A., Machann J., Schick F., Schraml C., Königsrainer A., Königsrainer I., Kröber S., Niess A., Fritsche A., Häring H.U., Stefan N. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009; 58 (9): 1281–1288. DOI: 10.1136/gut.2008.151977.Kantartzis K., Thamer C., Peter A., Machann J., Schick F., Schraml C., Königsrainer A., Königsrainer I., Kröber S., Niess A., Fritsche A., Häring H.U., Stefan N. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009; 58 (9): 1281–1288. DOI: 10.1136/gut.2008.151977.Liu W.Y., Lu D.J., Du X.M., Sun J.Q., Ge J., Wang R.W., Wang R., Zou J., Xu C., Ren J., Wen X.F., Liu Y., Cheng S.M., Tan X., Pekkala S., Munukka E., Wiklund P., Chen Y.Q., Gu Q., Xia Z.C., Liu J.J., Liu W.B., Chen X.B., Zhang Y.M., Li R., Borra R.J.H., Yao J.X., Chen P.J., Cheng S. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men – The role of gut microbiota composition: Study protocol for the AELC randomized controlled trial. BMC Public Health. 2014; 14: 48. DOI: 10.1186/1471-2458-14-48.Liu W.Y., Lu D.J., Du X.M., Sun J.Q., Ge J., Wang R.W., Wang R., Zou J., Xu C., Ren J., Wen X.F., Liu Y., Cheng S.M., Tan X., Pekkala S., Munukka E., Wiklund P., Chen Y.Q., Gu Q., Xia Z.C., Liu J.J., Liu W.B., Chen X.B., Zhang Y.M., Li R., Borra R.J.H., Yao J.X., Chen P.J., Cheng S. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men – The role of gut microbiota composition: Study protocol for the AELC randomized controlled trial. BMC Public Health. 2014; 14: 48. DOI: 10.1186/1471-2458-14-48.Kawaguchi T., Shiba N., Maeda T., Matsugaki T., Takano Y., Itou M., Sakata M., Taniguchi E., Nagata K., Sata M. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: A pilot study. J. Gastroenterol. 2011; 46 (6): 746–757. DOI: 10.1007/s00535-011-0378-x.Kawaguchi T., Shiba N., Maeda T., Matsugaki T., Takano Y., Itou M., Sakata M., Taniguchi E., Nagata K., Sata M. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: A pilot study. J. Gastroenterol. 2011; 46 (6): 746–757. DOI: 10.1007/s00535-011-0378-x.Oh S., Maruyama T., Eguchi K., Shida T., Arai E., Isobe T., Okamoto Y., Shoda J. Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: A pilot trial. Ther. Clin. Risk Manag. 2015; 11: 371–380. DOI: 10.2147/TCRM.S75109.Oh S., Maruyama T., Eguchi K., Shida T., Arai E., Isobe T., Okamoto Y., Shoda J. Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: A pilot trial. Ther. Clin. Risk Manag. 2015; 11: 371–380. DOI: 10.2147/TCRM.S75109.Hallsworth K., Fattakhova G., Hollingsworth K.G., Thoma C., Moore S., Taylor R., Day C.P., Trenell M.I. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011; 60 (9): 1278–1283. DOI: 10.1136/gut.2011.242073.Hallsworth K., Fattakhova G., Hollingsworth K.G., Thoma C., Moore S., Taylor R., Day C.P., Trenell M.I. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011; 60 (9): 1278–1283. DOI: 10.1136/gut.2011.242073.Strasser B., Siebert U., Schobersberger W. Resistance training in the treatment of the metabolic syndrome: A systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Medicine. 2010; 40 (5): 397–415. DOI: 10.2165/11531380-000000000-00000.Strasser B., Siebert U., Schobersberger W. Resistance training in the treatment of the metabolic syndrome: A systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Medicine. 2010; 40 (5): 397–415. DOI: 10.2165/11531380-000000000-00000.Strasser B., Arvandi M., Siebert U. Resistance training, visceral obesity and inflammatory response: A review of the evidence. Obesity Reviews. 2012; 13 (7): 578–591. DOI: 10.1111/j.1467-789X.2012.00988.x.Strasser B., Arvandi M., Siebert U. Resistance training, visceral obesity and inflammatory response: A review of the evidence. Obesity Reviews. 2012; 13 (7): 578–591. DOI: 10.1111/j.1467-789X.2012.00988.x.Baba C.S., Alexander G., Kalyani B., Pandey R., Rastogi S., Pandey A., Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21 (1 Pt 1): 191–198. DOI: 10.1111/j.1440-1746.2005.04233.x.Baba C.S., Alexander G., Kalyani B., Pandey R., Rastogi S., Pandey A., Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2006; 21 (1 Pt 1): 191–198. DOI: 10.1111/j.1440-1746.2005.04233.x.Lazo M., Solga S.F., Horska A., Bonekamp S., Diehl A.M., Brancati F.L., Wagenknecht L.E., Pi-Sunyer F.X., Kahn S.E., Clark J.M. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33 (10): 2156–2163. DOI: 10.2337/dc10-0856.Lazo M., Solga S.F., Horska A., Bonekamp S., Diehl A.M., Brancati F.L., Wagenknecht L.E., Pi-Sunyer F.X., Kahn S.E., Clark J.M. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33 (10): 2156–2163. DOI: 10.2337/dc10-0856.Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51 (1): 121–129. DOI: 10.1002/hep.23276.Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51 (1): 121–129. DOI: 10.1002/hep.23276.Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–357. DOI: 10.1002/hep.2936.7.Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–357. DOI: 10.1002/hep.2936.7.Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 1986; 24 (1): 67–74. DOI: 10.1097/00005650-198601000-00007. 71. Tan X., Patel I., Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). Inov. Pharm. 2014; 5 (3): 1–8. DOI: 10.24926/iip.v5i3.347.Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 1986; 24 (1): 67–74. DOI: 10.1097/00005650-198601000-00007. 71. Tan X., Patel I., Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). Inov. Pharm. 2014; 5 (3): 1–8. DOI: 10.24926/iip.v5i3.347.Morisky D., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 2008; 10 (5): 348–354. DOI: 10.1111/j.1751-7176.2008.07572.x.Morisky D., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 2008; 10 (5): 348–354. DOI: 10.1111/j.1751-7176.2008.07572.x.Николаев Н.А., Мартынов А.И., Драпкина О.М., Ливзан М.А., Моисеев С.В., Скирденко Ю.П., Бунова С.С., Викторова И.А., Задионченко В.С., Лазебник Л.Б., Малявин А.Г., Нелидова А.В., Нечаева Г.И., Пушкарева Л.А., Ребров А.П., Сайфутдинов Р.И., Совалкин В.И., Терентьев В.П., Тюрин В.П., Уразов В.П., Федосеев Г.Б., Ягода А.В., Якушин С.С., Ясницкий Л.Н. Первый российский консенсус по количественной оценке приверженности лечению (одобрен XII Национальным конгрессом терапевтов. Москва, 22–24 ноября 2017 г.). Терапия. 2018; 5: 11–32. DOI: 10.18565/therapy.2018.5.11-32.Николаев Н.А., Мартынов А.И., Драпкина О.М., Ливзан М.А., Моисеев С.В., Скирденко Ю.П., Бунова С.С., Викторова И.А., Задионченко В.С., Лазебник Л.Б., Малявин А.Г., Нелидова А.В., Нечаева Г.И., Пушкарева Л.А., Ребров А.П., Сайфутдинов Р.И., Совалкин В.И., Терентьев В.П., Тюрин В.П., Уразов В.П., Федосеев Г.Б., Ягода А.В., Якушин С.С., Ясницкий Л.Н. Первый российский консенсус по количественной оценке приверженности лечению (одобрен XII Национальным конгрессом терапевтов. Москва, 22–24 ноября 2017 г.). Терапия. 2018; 5: 11–32. DOI: 10.18565/therapy.2018.5.11-32.Николаев Н.А., Скирденко Ю.П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая фармакология и терапия. 2018; 27 (1): 74–78.Николаев Н.А., Скирденко Ю.П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая фармакология и терапия. 2018; 27 (1): 74–78.Trichopoulou A., Costacou T., Bamia C., Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N. Engl. J. Med. 2003; 348: 2599–2608. DOI: 10.1056/NEJMoa025039.Trichopoulou A., Costacou T., Bamia C., Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N. Engl. J. Med. 2003; 348: 2599–2608. DOI: 10.1056/NEJMoa025039.Panagiotakos D.B., Pitsavos C., Stefanadis C. Dietary patterns: A Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr. Metab. Cardiovasc. Dis. 2006; 16 (8): 559–568. DOI: 10.1016/j.numecd.2005.08.006.Panagiotakos D.B., Pitsavos C., Stefanadis C. Dietary patterns: A Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr. Metab. Cardiovasc. Dis. 2006; 16 (8): 559–568. DOI: 10.1016/j.numecd.2005.08.006.Tur J.A., Romaguera D., Pons A. The Diet Quality Index-International (DQI-I): is it a useful tool to evaluate the quality of the Mediterranean diet? Br. J. Nutr. 2005; 93 (3): 369–376. DOI: 10.1079/bjn20041363.Tur J.A., Romaguera D., Pons A. The Diet Quality Index-International (DQI-I): is it a useful tool to evaluate the quality of the Mediterranean diet? Br. J. Nutr. 2005; 93 (3): 369–376. DOI: 10.1079/bjn20041363.Kim S., Haines P.S., Siega-Riz A.M., Popkin B.M. The Diet Quality Index-International (DQI-I) provides an effective tool for cross-national comparison of diet quality as illustrated by China and the United States. J. Nutr. 2003; 133 (11): 3476– 3484. DOI: 10.1093/jn/133.11.3476.Kim S., Haines P.S., Siega-Riz A.M., Popkin B.M. The Diet Quality Index-International (DQI-I) provides an effective tool for cross-national comparison of diet quality as illustrated by China and the United States. J. Nutr. 2003; 133 (11): 3476– 3484. DOI: 10.1093/jn/133.11.3476.Mathurin P., Hollebecque A., Arnalsteen L., Buob D., Leteurtre E., Caiazzo R., Pigeyre M., Verkindt H., Dharancy S., Louvet A., Romon M., Pattou F. Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology. 2009; 137 (2): 532–540. DOI: 10.1053/j.gastro.2009.04.052.Mathurin P., Hollebecque A., Arnalsteen L., Buob D., Leteurtre E., Caiazzo R., Pigeyre M., Verkindt H., Dharancy S., Louvet A., Romon M., Pattou F. Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology. 2009; 137 (2): 532–540. DOI: 10.1053/j.gastro.2009.04.052.Kral J.G., Thung S.N., Biron S., Hould F.S., Lebel S., Marceau S., Simard S., Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004; 135 (1): 48–58. DOI: 10.1016/j.surg.2003.10.003.Kral J.G., Thung S.N., Biron S., Hould F.S., Lebel S., Marceau S., Simard S., Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004; 135 (1): 48–58. DOI: 10.1016/j.surg.2003.10.003.

The authors declare that there are no conflicts of interest present.